1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis COBRE funding opportunity, also part of the IDeA program, focuses on developing biomedical research capacity.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Institutions located in jurisdictions that have historically received low levels of NIH funding are eligible. Confirm the full requirements in the official notice before applying.
Centers of Biomedical Research Excellence: Development Phase (COBRE-D) (P30 – Clinical Trial Not Allowed) (PAR-27-054) is funded by National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) is sponsored by National Institutes of Health (NIH), Centers for Disease Control (CDC), and Food and Drug Administration (FDA). This program provides non-dilutive funding for early-stage research and development in biomedical and behavioral science, aligning with the missions of NIH, CDC, and FDA.
Small Business Technology Transfer (STTR) Program (Parent STTR [R41/R42]) is sponsored by National Institutes of Health (NIH), Department of Health and Human Services (HHS), Centers for Disease Control (CDC). This omnibus solicitation supports cooperative research and development between small businesses and non-profit research institutions to advance early-stage biomedical commercialization. It is designed to foster technology transfer.
Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). This program provides additional funding for small businesses that have successfully completed Phase II SBIR projects and require extraordinary time and effort in the R&D phase to reach the marketplace. It focuses on biomedical technologies with public health impact.
PAR-27-056 replaces the long-running IDeA-CTR U54 cooperative agreement with a P30 center core grant and splits the program into Development and Network tracks. Posted August 19, 2026, with a first estimated due date of October 9. Here is what the mechanism swap actually changes for the 23 IDeA states and Puerto Rico.
Read articleThe memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articlePAR-27-054 and PAR-27-055 replace COBRE's Phase 1-2-3 model with two tracks: a 15-year Development-Expansion-Sustainability path and a 10-year Expansion-Sustainability path. At $1.5 million per year in direct costs across 23 states and Puerto Rico, with new research cores prohibited in the final phase and eligibility capped at three active awards per institution, the track you claim is the most consequential choice in the application.
Read article